| Species |
Human |
| Protein Construction |
LILRB1/CD85j/ILT2 Domain1&2 (Gly24-Gly221)_x000D_
Accession # Q8NHL6-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized LILRB1/CD85j/ILT2 Domain1&2, His, Human at 5μg/ml (100μl/Well) on the plate can bind AntiLILRB1 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
23.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
LILRB1, also known as CD85j and IL-T2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family. Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs.LILRB1 is a receptor for class I MHC antigens. |
| Synonyms |
ILT2; ILT-2; ILT2FLJ37515; LILRB1; LIR1; MIR7; CD85J; XXbac-BCX85G21.4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
